

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

Original Issue Date (Created):	<b>5/3/2004</b>
Most Recent Review Date (Revised):	<b>4/23/2020</b>
<b>Effective Date:</b>	<b>10/1/2020</b>

[POLICY RATIONALE](#)  
[DISCLAIMER](#)  
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)  
[DEFINITIONS](#)  
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)  
[BENEFIT VARIATIONS](#)  
[REFERENCES](#)

**I. POLICY**

Mechanical insufflation-exsufflation (MI-E) may be considered **medically necessary** only in patients with neuromuscular disease or spinal cord injury and impaired ability to cough and who require non-invasive ventilatory assistance.

The presence of chronic obstructive pulmonary disease (COPD), bullous emphysema, known susceptibility to pneumothorax or pneumo-mediastinum, or exposure to recent barotrauma are considered relative contraindications to MI-E.

*Cross-references:*

**MP-6.015** Airway Clearance Devices

**MP-6.026** Durable Medical Equipment (DME) and Supplies

**II. PRODUCT VARIATIONS**

[TOP](#)

This policy is applicable to all programs and products administered by Capital BlueCross unless otherwise indicated below.

*Note* - The Federal Employee Program (FEP) Service Benefit Plan does not have a medical policy related to these services. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

**III. DESCRIPTION/BACKGROUND**

[TOP](#)

Normal clearance of airways rests on three (3) basic components: a patent airway, mucociliary clearance, and an adequate cough. Patients with spinal cord injuries or a variety of neuromuscular diseases or chest wall deformities may have impaired cough responses, which may lead to respiratory failure during respiratory tract infections due to the inability to clear the profuse respiratory secretions. Chest wall deformities may include kyphosis, scoliosis, or lordosis, while neuromuscular diseases include muscular dystrophy, poliomyelitis, spinal muscle

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

atrophy, myasthenia gravis, amyotrophic lateral sclerosis, or cerebral palsy. The great majority of neuromuscular disease morbidity and mortality is related to respiratory muscle weakness, and the vast majority of episodes of respiratory failure occur during otherwise benign episodes of respiratory tract infections. Chest infections may result in repeated episodes of pneumonia, repeated hospitalizations, and finally, in tracheostomy with mechanical ventilation.

The normal cough consists of 4 stages: 1) A precough inspiration to about 85% of total lung capacity; 2) Followed by closure of the glottis; 3) Development of thoracoabdominal pressure sufficient to generate an explosive decompression of the chest at glottic opening; and 4) Opening of the glottis with exsufflation. The peak cough expiratory force typically exceeds 5L/sec, with total expiratory volume of about 2.3L. In general, an impaired ability to cough has been defined as a peak cough expiratory flow of less than 2-3L per second.

A variety of techniques have been developed to enhance each of these stages. For example, manually assisted coughing is designed to enhance exsufflation and consists of abdominal pressure delivered by a caregiver timed with the glottic opening. Manual assisted coughing may be offered to patients with a peak cough expiratory flow of less than 5L/ sec, but is less effective in the presence of scoliosis or obesity or after meals. Glossopharyngeal breathing is a technique to increase inspiratory flow and is commonly used in patients with a decreased vital capacity due to inspiratory muscle paralysis. This breathing technique involves the use of the tongue and pharyngeal muscles to add to an inspiratory effort by projecting (gulping) boluses of air past the glottis.

Mechanical insufflation-exsufflation is designed to deliver alternative cycles of positive and negative pressure. One such device, the CoughAssist, is a portable electric device which utilizes a blower and valve to alternately apply a positive and then a negative pressure to a patient’s airway in order to assist the patient in clearing retained bronchopulmonary secretions. Air is delivered to and from the patient via a breathing circuit incorporating a flexible tube, a bacterial filter and either a facemask, a mouthpiece or an adapter to a tracheostomy or endotracheal tube. Physicians, respiratory therapists, nurses and trained family members may administer this therapy.

Mechanical in-exsufflation (MI-E) has been used in a variety of patient populations as an adjunct to noninvasive ventilation using intermittent positive pulmonary ventilation (IPPV) (delivered nasally or orally). For example, many patients with neuromuscular disease or chest wall deformities with progressive ventilatory failure will use noninvasive IPPV either nocturnally or throughout the day, depending on such parameters as vital capacity and oxygenation levels. Patients managed at home with noninvasive IPPV may monitor oxygen desaturation levels. A sudden decrease in oxygen desaturation may prompt the use of MI-E to eliminate the presumed offending mucus plug. Advocates of MI-E state that even patients requiring 24 hour IPPV can be managed noninvasively for prolonged periods of time without hospitalization using this technique. In patients with tracheostomies, MI-E has been used as an alternative or complement to suctioning. In addition, it is suggested that MI-E is more comfortable to the patient than suctioning. MI-E may either be offered on a temporary basis in patients with noninvasive IPPV

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

who are suffering from a respiratory tract illness, or may be used on a more chronic basis in an attempt to avoid the option of invasive tracheostomy and suctioning.

**IV. RATIONALE**

[TOP](#)

**Summary**

The published data suggest that MI-E can improve the intermediate outcome of peak cough expiratory flow. In some studies, patients have served as their own control, with a decreased incidence of hospitalization among patients who switch from tracheostomy to a noninvasive approach, which may include MI-E as one component. While controlled trials would ideally further delineate who is most likely to benefit from MI-E, particularly those who would benefit from having such a device in the home, such trials are logistically difficult. The heterogeneous nature of the patients, even among those with similar diseases, almost mandates a case by case approach for these patients. For example, the clinical utility of MI-E would not only depend on the physiologic parameters of lung function, but also on the tempo of the disease course, the availability of home caregivers, and patient preference and motivation. The non-investigational status for the MI-E device is based on these considerations.

**V. DEFINITIONS**

[TOP](#)

**EXSUFFLATION** is the forceful expulsion of air from a cavity by artificial means, such as the use of a mechanical exsufflator.

**GLOSSOPHARYNGEAL** refers to the tongue and pharynx.

**INSUFFLATION** is the act of blowing a gas, vapor, or powder into a cavity, such as the lungs.

**INTERMITTENT POSITIVE PRESSURE** refers to a mechanical method for assisting pulmonary ventilation employing a device that administers air or oxygen for the inflation of the lungs under positive pressure. Synonym: intermittent positive pressure ventilation (IPPV).

**TRACHEOSTOMY** refers to an incision of the trachea through the skin and muscles of the neck overlying the trachea.

**VI. BENEFIT VARIATIONS**

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member's benefit information or contact Capital BlueCross for benefit information.

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

**VII. DISCLAIMER**

[TOP](#)

*Capital BlueCross’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.*

**VIII. CODING INFORMATION**

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Covered when medically necessary:**

<b>HCPCS Code</b>	<b>Description</b>
A7020	Interface for cough stimulating device, includes all components, replacement only
E0482	Cough stimulating device, alternating positive and negative airway pressure

<b>ICD-10-CM Diagnosis Code</b>	<b>Description</b>
B91	Sequelae of poliomyelitis
E74.02	Pompe disease
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
G12.1	Other inherited spinal muscular atrophy
G12.20	Motor neuron disease, unspecified
G12.21	Amyotrophic lateral sclerosis
G12.22	Progressive bulbar palsy
G12.23	Primary lateral sclerosis
G12.24	Familial motor neuron disease
G12.25	Progressive spinal muscle atrophy
G12.29	Other motor neuron disease
G12.8	Other spinal muscular atrophies and related syndromes
G12.9	Spinal muscular atrophy, unspecified
G14	Postpolio syndrome
G35	Multiple sclerosis
G70.01	Myasthenia gravis with (acute) exacerbation
G71.00	Muscular dystrophy, unspecified

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

G71.01	Duchenne or Becker muscular dystrophy
G71.02	Facioscapulohumeral muscular dystrophy
G71.09	Other specified muscular dystrophies
G71.11	Myotonic muscular dystrophy
G71.12	Myotonia congenita
G71.13	Myotonic chondrodystrophy
G71.14	Drug induced myotonia
G71.19	Other specified myotonic disorders
G71.2	Congenital myopathies
G71.20	Congenital myopathies, unspecified
G71.21	Nemaline Myopathy
G71.22	Centronuclear Myopathy
G71.220	X-linked myotubular myopathy
G71.228	Other centronuclear myopathy
G71.29	Other congenital myopathy
G71.3	Mitochondrial myopathy, not elsewhere classified
G71.8	Other primary disorders of muscles
G71.9	Primary disorder of muscle, unspecified
G72.0	Drug-induced myopathy
G72.1	Alcoholic myopathy
G72.2	Myopathy due to other toxic agents
G72.3	Periodic paralysis
G72.41	Inclusion body myositis [IBM]
G72.49	Other inflammatory and immune myopathies, not elsewhere classified
G72.81	Critical illness myopathy
G72.89	Other specified myopathies
G72.9	Myopathy, unspecified
G73.7	Myopathy in diseases classified elsewhere
G82.50	Quadriplegia, unspecified
G82.51	Quadriplegia, C1-C4 complete
G82.52	Quadriplegia, C1-C4 incomplete
G82.53	Quadriplegia, C5-C7 complete
G82.54	Quadriplegia, C5-C7 incomplete

**IX. REFERENCES**

[TOP](#)

1. *Bach JR. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest 1993; 104(5):1553-62.*

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

2. *Bach HR. Update and perspective on noninvasive respiratory muscle aids. Part 2: The expiratory aids. Chest 1994; 105(5):1538-44.*
3. *Tzeng AC, Bach JR. Prevention of pulmonary morbidity for patients with neuromuscular disease. Chest 2000; 118(5):1390-6.*
4. *Bach JR, Isikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 1997; 112(4):1024-8.*
5. *Bach JR, Niranjana V, Weaver B. Spinal muscular atrophy type I: a noninvasive respiratory management approach. Chest 2000;117(4):1100-5.*
6. *Bach JR, Baird JS, Plosky D, et al. Spinal muscular atrophy type I: management and outcomes. Pediatric Pulmonol 2002; 34(1):16-22.*
7. *Bach JR, Wang TG. Noninvasive long-term ventilatory support for individuals with spinal muscular atrophy and functional bulbar musculature. Arch Phys Med Rehab 1995; 76(3):213-7.*
8. *Bach JR. A comparison of long-term ventilatory support alternatives from the perspective of the patient and care giver. Chest 1993; 104(6):1702-6.*
9. *Garstang SV, Kirshblum SC, Wood KE. Patient preference for in-exsufflation for secretion management with spinal cord injury. J Spinal Cord Med 2000; 23(2):80-5.*
10. *Brown, R, DiMarco, AF, Hoit, JD, and Garshick, E. Respiratory dysfunction and management in spinal cord injury. Respir Care. 2006; 51(8):853-868.*
11. *Epstein S. Respiratory muscle weakness due to neuromuscular disease: Management. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; updated March 23, 2020. [Website]: www.uptodate.com. Accessed April 22, 2020.*
12. *Fauroux, B, Guillemot, N, Aubertin, G, Nathan, N, Labit, A, Clement, A, and Lofaso, F. Physiologic benefits of mechanical insufflation-exsufflation in children with neuromuscular diseases. Chest. 2008; 133(1):161-168.*
13. *Homnick, DN. Mechanical insufflation-exsufflation for airway mucus clearance. Respir Care. 2007;52(10):1296-1305.*
14. *Kang SW. Pulmonary rehabilitation in patients with neuromuscular disease. Yonsei Med J 2006; 47 (3): 307-14.*
15. *Pillastrini, P, Bordini, S, Bazzocchi, G, Belloni, G, and Menarini, M. Study of the effectiveness of bronchial clearance in subjects with upper spinal cord injuries: examination of a rehabilitation program involving mechanical insufflation and exsufflation. Spinal Cord. 2006; 44(10):614-616.*
16. *Simonds, AK. Recent advances in respiratory care for neuromuscular disease. Chest. 2006; 130(6):1879-1886.*
17. *Auger C, Hernando V, Galmiche H. Use of Mechanical Insufflation-Exsufflation Devices for Airway Clearance in Subjects With Neuromuscular Disease. Respir Care. 2017;62(2):236–245. doi:10.4187/respcare.04877*
18. *Blue Cross Blue Shield Association Medical Policy Reference Manual. 1.01.21, Mechanical Insufflation-Exsufflation as a Expiratory Muscle Aid. (Archived July 2010).*

Other:

<b>POLICY TITLE</b>	<b>MECHANICAL INSUFFLATION-EXSUFFLATION DEVICE</b>
<b>POLICY NUMBER</b>	<b>MP-6.022</b>

1. *Taber’s Cyclopedic Medical Dictionary, 20th edition.*

**X. POLICY HISTORY**

[TOP](#)

<b>MP 6.022</b>	<b>CAC 12/2/03</b>
	<b>CAC 5/31/05</b>
	<b>CAC 5/30/06 Consensus</b>
	<b>CAC 1/30/07 Milliman Criteria</b>
	<b>CAC 11/27/07</b>
	<b>CAC 11/25/08</b>
	<b>CAC 9/29/09 Consensus - policy statement unchanged, references updated</b>
	<b>CAC 11/30/10 Consensus</b>
	<b>CAC 11/22/11 Consensus review</b>
	<b>4/08/13- Admin code review.</b>
	<b>7/19/13 Admin coding review complete</b>
	<b>CAC 9/24/13 Consensus review.</b> References updated but no changes to the policy statements.
	<b>CAC 9/30/14 Consensus review.</b> References updated. No changes to the policy statements. Rationale added. Coding reviewed.
	<b>CAC 9/29/15 Consensus review.</b> References reviewed. No change to policy statements. Coding reviewed and unranked. LCD changed from L12872 to L33795
	<b>7/15/16 Administrative posting.</b> LCD revised to reflect Noridian LCD L33795.
	<b>CAC 9/27/16 Consensus review.</b> No changes to the policy statements. Variations reformatted.
	<b>CAC 9/26/17 Consensus review.</b> Policy statement unchanged. References updated. Coding updated. Added new ICD 10 codes effective from 10/1/17.
	<b>1/1/18 Admin Update:</b> Medicare variations removed from Commercial Policies.
	<b>6/8/18 Consensus review.</b> No changes to the policy statements. Rationale condensed. References updated.
	<b>10/1/18 Admin Update:</b> Removed deleted ICD-10 codes, added new ICD-10 codes effective 10/1/18. <b>10/29/18 Consensus Coding Review.</b> No Changes.
<b>4/15/19 Consensus review.</b> No changes to policy statement. References updated.	
<b>4/23/20 Consensus review.</b> No changes to policy statement. Coding reviewed, added diagnosis codes E74.02 and G70.01. References updated.	
<b>9/2/20 Admin update.</b> ICD codes added, G71.20, G71.21, G71.22, G71.220, G71.228, G71.29	

[TOP](#)

*Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.*